Cargando…

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Climent, Elisenda, Pérez-Calahorra, Sofía, Marco-Benedí, Victoria, Plana, Nuria, Sánchez, Rosa, Ros, Emilio, Ascaso, Juan F., Puzo, Jose, Almagro, Fátima, Lahoz, Carlos, Civeira, Fernando, Pedro-Botet, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514105/ https://www.ncbi.nlm.nih.gov/pubmed/28717233 http://dx.doi.org/10.1038/s41598-017-06101-6

Ejemplares similares

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy
por: Marco-Benedí, Victoria, et al.
Publicado: (2019)

Familial Hypercholesterolemia: Do HDL Play a Role?
por: Pedro-Botet, Juan, et al.
Publicado: (2021)

Hydrophilic or Lipophilic Statins?
por: Climent, Elisenda, et al.
Publicado: (2021)

Association between non-cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia
por: Baila-Rueda, Lucía, et al.
Publicado: (2018)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia
por: De Castro-Orós, Isabel, et al.
Publicado: (2014)

Bariatric surgery and LDL cholesterol (BASALTO) trial study protocol: randomised controlled study evaluating the effect of gastric bypass versus sleeve gastrectomy on high LDL cholesterol
por: Benaiges, David, et al.
Publicado: (2020)

Statins for primary cardiovascular prevention in the elderly
por: Pedro-Botet, Juan, et al.
Publicado: (2015)

Current causes of death in familial hypercholesterolemia
por: Marco-Benedí, Victoria, et al.
Publicado: (2022)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

The Forgotten Gastrointestinal Tract in COVID-19 Infection
por: Pedro-Botet, Juan, et al.
Publicado: (2020)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Association of Achilles tendon thickness and LDL-cholesterol levels in patients with hypercholesterolemia
por: Wang, Bei, et al.
Publicado: (2018)

The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia
por: Korneva, Victoria, et al.
Publicado: (2022)

Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?
por: Habon, Tamas, et al.
Publicado: (2016)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
por: Tada, Hayato, et al.
Publicado: (2021)

Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
por: Kim, Kyungpil, et al.
Publicado: (2014)

Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
por: Mata, Nelva, et al.
Publicado: (2011)

Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation
por: Scicali, Roberto, et al.
Publicado: (2019)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy
por: Masana, Lluís, et al.
Publicado: (2020)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
por: Postmus, Iris, et al.
Publicado: (2014)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Bariatric Surgery and Hypertension
por: Climent, Elisenda, et al.
Publicado: (2021)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia
por: Šálek, Tomáš, et al.
Publicado: (2023)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines
por: Ross, Elsie Gyang, et al.
Publicado: (2016)

Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?
por: Han, Ki Hoon
Publicado: (2019)

Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol
por: Sim, Doo Sun, et al.
Publicado: (2019)

Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
por: Sakuma, Masashi, et al.
Publicado: (2022)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase
por: Filippov, Sergey, et al.
Publicado: (2014)

Plant sterols–enriched diet decreases small, dense LDL-cholesterol levels in children with hypercholesterolemia: a prospective study
por: Garoufi, Anastasia, et al.
Publicado: (2014)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
por: Tada, Hayato, et al.
Publicado: (2020)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qtndt8gmefnqgbak27fegivgc8